Digestive System TRIZ Cases
- Conjugated Polyelectrolyte Markers for Spectral Analyte Classification
Conjugated polyelectrolyte markers use selected fluorescence wavelengths to classify diverse analytes with lower computational complexity.
- Resin Acid-Based Feed Supplement for Intestinal Disorder Prevention
A resin acid-based supplement inhibits harmful bacteria to prevent intestinal disorders without relying on regulated antibiotics.
- Mesenchymal Stem Cells for Refractory Oral Inflammation
Persistent oral inflammation can require continuous therapy; MSC delivery targets immune dysregulation to mitigate symptoms and improve quality of life.
- Carborane ERβ Agonists for Selective Receptor Binding
Structural modification of carborane ligands targets ERβ while limiting undesirable ERα activation in fibrotic disease treatment.
- In Vitro MMP Profiling for Ulcerative Colitis Anti-TNF Response
Measuring MMP expression in peripheral blood mononuclear cells helps classify ulcerative colitis patients before anti-TNF treatment.
- M-63 Infant Probiotic Composition for Early Gut Colonization
M-63 probiotic cells, cultures, or treated products promote early Bifidobacterium colonization and intestinal maturation in infants.
- Lactobacillus Rhamnosus HL-200 Ethanolamine Metabolism for Leaky Gut
Human-derived Lactobacillus rhamnosus HL-200 metabolizes ethanolamine and modulates the ARID3a/miR101a-3p/Tjp1 axis to reduce gut permeability.
- pH-Dependent Anti-HBsAg Antibody for Extended HBV Suppression
Neutral-pH binding helps anti-HBsAg antibodies clear HBV while Fc engineering extends antigen suppression and reduces treatment frequency.
- Cyclosporine Analogue Composition for Non-Liver Fibrosis Treatment
CRV431 addresses limited antifibrotic options by reducing, delaying, and reversing fibrosis across lung, kidney, heart, and skin.
- α4β7 Antibody Multidose Regimens for Inflammatory Bowel Disease
An α4β7 antibody multidose regimen sustains efficacy while reducing administration frequency for inflammatory bowel disease.
- miR-412 Control of Hepatic Stellate Cell Activation and Fibrosis
Activated hepatic stellate cells can drive fibrosis; miR-412 and miR-15a restore quiescence by reducing activation markers.